Stellar Biotechnologies, Inc. (SBOTF) is a publicly-held corporation that was founded to address the growing need for Keyhole Limpet Hemocyanin (KLH) protein. Today, they are the world leader in the development and manufacture of high quality KLH products for pharmaceutical use. The company has set unprecedented benchmarks in the proprietary ability to sustainably create GMP grade KLH. They currently operate the only KLH production facility of its kind in the world.
Based in Port Hueneme, California, Stellar Biotechnologies has grown due to its innovative and proactive approach to acquiring sustainable, commercial-grade quantities of KLH for biopharma arenas. KLH has become a significant and versatile molecule that works to stimulate the immune system. It has a long, effective and safe history in the treatment of Alzheimer’s, inflammatory disease, and various types of cancer and new uses are being found each year.
As a world leader in providing KLH-based immunotherapies, Stellar Biotechnologies is also developing its own KLH-conjugate active immunotherapy in order to treat Clostridium difficile infection. The versatility of the KLH molecule has established a consistent requirement for commercial-scale GMP grade KLH, as well as unlimited commercial opportunities for future growth. Among Stellar’s global partners are multinational pharmaceutical companies and distinguished research centers.
Stellar Biotechnologies has utilized decades of specialized aquaculture science to overcome numerous pharmaceutical industry challenges and create an innovative Stellar KLH™ platform that powers the growing field of disease-targeting immune therapies for the modern medical industry. Additionally, Stellar holds key intellectual property directly associated with aquaculture systems, cultivation and protection of the Giant Keyhole Limpet (Megathura crenulata).
Stellar Biotechnologies, Inc. partners with the University of Guelph, Amaran Biotechnology, Bayer Innovations and Neovacs among others. They have over 15 years of KLH production experience, specializing in the controlled production of fully traceable GMP grade KLH. As of May 31, 2014, Stellar showed shareholder’s equity of $11.1 million with about 78 million shares outstanding. Cash and cash equivalents as of May 31, 2014 were $14.8 million, compared to $7.9 million at year-end August 31, 2013.